Synergistic Cancer Treatment System with AI, IoT, Blockchain, and Nanoparticle Delivery
Legal Citation
Summary of the Inventive Concept
A novel cancer treatment system integrating a fusion protein dimer with IL-2 and CD80 proteins, an anticancer agent, and advanced technologies like AI, IoT, blockchain, and nanoparticle delivery to enhance treatment efficacy, patient monitoring, and data management.
Background and Problem Solved
The original patent disclosed a pharmaceutical composition for cancer treatment comprising a fusion protein dimer and an anticancer agent. However, this invention has limitations in terms of treatment monitoring, data management, and personalized treatment strategies. The new inventive concept addresses these limitations by integrating distinct technologies to create a more powerful and effective system.
Detailed Description of the Inventive Concept
The system comprises a fusion protein dimer including IL-2 protein and CD80 protein, an anticancer agent, and a blockchain-based data storage module for tracking patient treatment history and outcomes. Additionally, the system incorporates an AI-powered algorithm for predicting treatment efficacy based on patient-specific biomarkers and a nanoparticle-based delivery system for targeted and controlled release of the fusion protein and anticancer agent. The system may also include an IoT-based wearable device for monitoring patient vital signs and adjusting treatment dosages in real-time.
Novelty and Inventive Step
The new claims introduce novel and non-obvious synergies between the fusion protein dimer, anticancer agent, and advanced technologies like AI, IoT, blockchain, and nanoparticle delivery. The inventive step lies in the integration of these distinct technologies to create a more effective and personalized cancer treatment system.
Alternative Embodiments and Variations
Alternative embodiments may include different AI algorithms, IoT devices, or nanoparticle delivery systems. Variations may also include integrating other advanced technologies, such as gene editing or immunotherapy, to further enhance treatment outcomes.
Potential Commercial Applications and Market
The synergistic cancer treatment system has significant commercial potential in the pharmaceutical and healthcare industries, particularly in the areas of personalized medicine and cancer treatment. The system's ability to enhance treatment efficacy, monitor patient outcomes, and manage data securely makes it an attractive solution for healthcare providers and patients.
CPC Classifications
| Section | Class | Group |
|---|---|---|
| A | A61 | A61K38/2013 |
| A | A61 | A61K31/337 |
| A | A61 | A61K31/444 |
| A | A61 | A61K31/4439 |
| A | A61 | A61K31/47 |
| A | A61 | A61K31/4709 |
| A | A61 | A61K31/502 |
| A | A61 | A61K31/506 |
| A | A61 | A61K31/5025 |
| A | A61 | A61K31/519 |
| A | A61 | A61K31/708 |
| A | A61 | A61K33/243 |
| A | A61 | A61K38/1774 |
| A | A61 | A61K39/3955 |
| A | A61 | A61K45/06 |
| A | A61 | A61P35/00 |
Original Patent Information
| Patent Number | US 11,857,601 |
|---|---|
| Title | Pharmaceutical composition for cancer treatment comprising fusion protein including IL-2 protein and CD80 protein and anticancer drug |
| Assignee(s) | GI Innovation, Inc. |